VistaGen Therapeutics (NASDAQ:VTGN) Downgraded to “Hold” Rating by Stifel Nicolaus

VistaGen Therapeutics (NASDAQ:VTGN) was downgraded by investment analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday,Finviz reports. They currently have a $1.00 target price on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 25.47% from the stock’s current price.

A number of other brokerages have also recently issued reports on VTGN. William Blair reissued an “outperform” rating on shares of VistaGen Therapeutics in a research note on Tuesday, October 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $1.00.

VistaGen Therapeutics Trading Down 81.7%

VTGN stock traded down $3.56 on Wednesday, hitting $0.80. The company had a trading volume of 31,639,389 shares, compared to its average volume of 493,772. VistaGen Therapeutics has a 12-month low of $0.75 and a 12-month high of $5.14. The stock has a market cap of $31.47 million, a price-to-earnings ratio of -0.42 and a beta of 0.56. The stock’s 50-day simple moving average is $4.20 and its 200 day simple moving average is $3.32.

VistaGen Therapeutics (NASDAQ:VTGN) last announced its earnings results on Thursday, November 13th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The company had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.16 million. Research analysts forecast that VistaGen Therapeutics will post -1.77 earnings per share for the current year.

Hedge Funds Weigh In On VistaGen Therapeutics

Large investors have recently made changes to their positions in the company. Stempoint Capital LP boosted its holdings in VistaGen Therapeutics by 2.0% during the 2nd quarter. Stempoint Capital LP now owns 2,413,254 shares of the company’s stock valued at $4,827,000 after acquiring an additional 46,700 shares during the period. ADAR1 Capital Management LLC lifted its holdings in VistaGen Therapeutics by 246.4% during the 1st quarter. ADAR1 Capital Management LLC now owns 420,765 shares of the company’s stock valued at $1,052,000 after buying an additional 299,304 shares in the last quarter. Two Sigma Investments LP boosted its position in VistaGen Therapeutics by 223.5% in the 3rd quarter. Two Sigma Investments LP now owns 289,409 shares of the company’s stock valued at $1,027,000 after buying an additional 199,958 shares during the period. AdvisorShares Investments LLC grew its stake in VistaGen Therapeutics by 1.9% in the 3rd quarter. AdvisorShares Investments LLC now owns 206,998 shares of the company’s stock worth $735,000 after acquiring an additional 3,884 shares in the last quarter. Finally, Boothbay Fund Management LLC grew its stake in VistaGen Therapeutics by 10.8% in the 3rd quarter. Boothbay Fund Management LLC now owns 197,024 shares of the company’s stock worth $699,000 after acquiring an additional 19,166 shares in the last quarter. 78.39% of the stock is owned by hedge funds and other institutional investors.

VistaGen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.